Here are five insights:
1. Amgen is leading the $25 million financing round.
2. The startup, Fortuna Fix, is striving to develop novel techniques for re-growing damaged neural tissue.
3. Fortuna Fix has re-engineered multipotent stem cells into neural stem cells.
4. The idea is providers can inject these cells into patients multiple times, creating a treatment processes for tissue regeneration.
5. This investment reflects Amgen’s first in the regenerative medicine space.
More articles on biologics:
Global spine biologics market to expand at 2% CAGR through 2020: 5 insights
Stanford creates gel for neural stem cell regeneration: 6 things to know
Xtant Medical, curasan enter distribution agreement: 5 things to know
